Canagliflozin and Cardiovascular disease- results of the CANVAS trial

• Hlavní autoři: Syed Raza Shah (Autor), Najla Issa Najim (Autor), Zainab Abbasi (Autor), Mazia Fatima (Autor), Ayesha Altaf Jangda (Autor), Waqas Shahnawaz (Autor), Maira Shahid (Autor), Syed Arbab Shah (Autor)
• Médium: Kniha
• Vydáno: Greater Baltimore Medical Center, 2018-09-01T00:00:00Z.
• Témata: article
• On-line přístup: Connect to this object online.

Canagliflozin is a new novel oral antidiabetic agent belonging to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors, inhibiting glucose reabsorption in the proximal tubule, leading to increased urinary glucose excretion and subsequently to reduction in plasma glucose concentration, in...